In conclusion, our data demonstrate that the combination of two promising anti-leukaemia approaches using mefloquine (6) or mTOR inhibition (21) exceeds by far the reported effects of a single treatment without any detectable increase in the toxicity. The gene discussed is MTOR; the disease is leukemia.